Clinical manifestations and mortality among hospitalized COVID-19 patients in Tanzania, 2021-2022

Author:

Osati ElishaORCID,Shayo Grace A.,Nagu Tumaini,Sangeda Raphael ZORCID,Moshiro Candida,Adams Naveeda,Ramadhani Athumani,Wanja BahatiORCID,Muniko Albert,Seni Jeremia,Nicholaus Mary A.ORCID,Kilonzo Kajiru GORCID,Nyaisonga Gervas,Mbije Christian,Meda John,Rainer Denis,Nkya Martha,Mhame Paulo,Samwel LucyORCID,Vumilia Liggyle,Shekalaghe Seif,Makubi Abel

Abstract

BackgroundThere have been differential mortality rates from Corona Virus Disease of 2019 (COVID-19) in different parts of the world. It is not clear whether the clinical presentation does also differ, thus the need for this study in a Sub-Saharan African country. The aim of this study was to describe clinical manifestations and outcome of patients diagnosed with COVID-19 in selected tertiary hospitals in Tanzania.Methods and FindingsA retrospective analysis of archived data from 26thMarch, 2021 to 30thSeptember, 2022 was done for adults aged ≥18 years who were admitted in five tertiary-level hospitals in Tanzania. Information collected included socio-demographic, radiological and clinical characteristics of the patients as well as outcome of the admission (discharge vs death). Categorical variables were presented as frequencies and proportions and compared using Chi square test. Logistic regression was used to assess the relationship between COVID-19 mortality and the collected variables. Out of 1387 COVID-19 patients, approximately 52% were males. The median age was 60 years [(IQR)= (19-102)). The most common symptoms were dyspnea (943,68%), cough (889, 64%), fever (597,43%) and fatigue (570, 41%). In hospital mortality was (476, 34%). Mortality significantly increased with increasing age, being the most in age >90 years [aOR (95% CI) =6.72 (1.94-20.81), P<0.001. Other predictors of death were not possessing a health insurance, [aOR (95% CI) = 2.78 (2.09-3.70), P<0. 001], dyspnea [aOR (95% CI) = 1.40(1.02-2.06), P=0.03]; chest pain, [aOR (95% CI) = 1.78 (1.12-3.21), P=0.03]; HIV positivity, [aOR (95% CI) = 4.62 (2.51-8.73), P<0.001]; neutrophilia, [aOR (95% CI) = 1.02 (1.01 – 1.03), P=0.02]; none use of ivermectin, [aOR (95% CI) = 1.46 (1.09 – 2.22), P=0.02] and non-use of steroid, [aOR (95% CI) = 1.40 (1.2 – 2.5), P=0.04]. Retrospective nature of this study which based on documented patients records, with a large number of patients left out of the analysis due to missed data, this might in a way affect the results of the present study.ConclusionsThe most common presenting symptoms were dyspnea, cough and fever, just as what was common elsewhere in the world. Mortality increased significantly with age, in HIV-infected patients, in those without a health insurance, those presenting with dyspnea, chest pain, or neutrophilia and those who did not use steroid or ivermectin. Clinicians should actively look for the predictors of mortality and take appropriate management to reduce mortality.

Publisher

Cold Spring Harbor Laboratory

Reference54 articles.

1. World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. WHO Document Production Services, Geneve Switzerland. Published 2023. Accessed March 8, 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019

2. WHO. Tuberculosis deaths and disease increase during the COVID-19 pandemic. WHO Newsletters News release 27th October. Published online 2022. Accessed April 15, 2023. https://www.who.int/news/item/27-10-2022-tuberculosis-deaths-and-disease-increase-during-the-covid-19-pandemic

3. UNAIDS Global AIDS Monitoring 2020. Country Progress Report-United Republic of Tanzania Global AIDS Monitoring 2020.; 2020. Accessed April 15, 2023. https://www.unaids.org/sites/default/files/country/documents/TZA_2020_countryreport.pdf

4. The Science Underlying COVID-19_ Implications for the Cardiovascular System - PubMed.

5. Potential Effects of Coronaviruses on the Cardiovascular System_ A Review - PubMed.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3